Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 27777972.
- Also identified by DOI 10.1172/jci.insight.87754 and PMC identifier 5070952.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Current antiangiogenesis therapy relies on inhibiting newly developed immature tumor blood vessels and starving tumor cells. This strategy has shown transient and modest efficacy. Here, we report a better approach to target cancer-associated endothelial cells (ECs), reverse permeability and leakiness of tumor blood vessels, and improve delivery of chemotherapeutic agents to the tumor. First, we identified deregulated microRNAs (miRs) from patient-derived cancer-associated ECs. Silencing these miRs led to decreased vascular permeability and increased maturation of blood vessels. Next, we screened a thioaptamer (TA) library to identify TAs selective for tumor-associated ECs. An annexin A2-targeted TA was identified and used for delivery of miR106b-5p and miR30c-5p inhibitors, resulting in vascular maturation and antitumor effects without inducing hypoxia. These findings could have implications for improving vascular-targeted therapy.
Medical subject headings
- Antineoplastic Agents
- Aptamers, Nucleotide
- Endothelial Cells
- MicroRNAs
- Neovascularization, Pathologic